News | May 09, 2024
Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The product is used to treat amyotrophic lateral sclerosis
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
